A new variant of the coronavirus, known as BA.3.2 or “Cicada,” is raising global concerns as it begins to spread, particularly within the United States. The emergence of this variant is prompting renewed attention to its potential to evade existing immunity, whether acquired through vaccination or prior infection. Although overall COVID-19 infection rates remain relatively low, the variant’s genetic characteristics are causing experts to closely monitor its trajectory.
Data from the Centers for Disease Control and Prevention (CDC) indicates that the Cicada variant has been identified in at least 25 U.S. States as of mid-February 2026, according to reporting from TODAY. This spread is occurring against a backdrop of declining public health surveillance globally, making accurate tracking of the variant’s reach more challenging. The situation underscores the ongoing need for vigilance and continued genomic sequencing efforts to understand the evolving nature of the virus.
A Highly Mutated Variant Attracts Scientific Scrutiny
Experts emphasize that the Cicada variant is distinguished by a significant number of genetic changes, particularly within the spike protein – the component of the virus responsible for entering human cells. These alterations differentiate it from currently circulating strains. Andrew Pekosz, a virologist, explained that these changes could make the variant appear “different” to the immune system, potentially reducing the effectiveness of protection gained from previous vaccinations or infections. This immune evasion potential is a key driver of the current concern.
The World Health Organization (WHO) classified the variant as a “Variant Under Monitoring” (VUM) in December 2025, citing its notable genetic properties. This designation signals the need for increased surveillance and research to better understand the variant’s characteristics and potential impact on public health. The WHO’s monitoring system is designed to quickly identify and assess emerging threats.
From South Africa to Global Circulation
The Cicada variant was first detected in South Africa in November 2024. We see a descendant of the Omicron variant, but has since evolved independently. After a period of slow spread, the variant began to expand globally in the fall of 2025, reaching more than 23 countries. Higher proportions of cases have been reported in several European nations, including Denmark, Germany, and the Netherlands. This geographic spread highlights the virus’s continued ability to cross borders and establish itself in new populations.
Severity of Illness: What Do We Know So Far?
Despite concerns about its ability to mutate, experts currently state there is no evidence to suggest that the Cicada variant causes more severe illness or leads to increased hospitalization rates compared to previous variants. Adolfo Garcia, a researcher studying the variant, noted that it doesn’t appear to be more dangerous, although it may cause unpleasant symptoms. Still, researchers caution that ongoing monitoring is crucial, as the variant’s behavior could change over time.
Is a New Wave of COVID-19 Imminent?
As of now, data does not indicate that the Cicada variant has triggered a widespread surge in infections. Its spread remains relatively limited, and it has not yet overtaken dominant strains. However, experts warn that continued monitoring is essential, particularly given the decline in global epidemiological surveillance. Reduced testing and reporting rates make it more difficult to accurately assess the variant’s true prevalence and potential for growth.
Recognizing Cicada Variant Symptoms
The symptoms associated with the new variant are similar to those of traditional COVID-19, including:
- Cough
- Fever or chills
- Sore throat
- Nasal congestion
- Shortness of breath
- Loss of smell or taste
- Fatigue and headache
- Vomiting or diarrhea
Medical professionals emphasize that these symptoms can overlap with those of the common cold and influenza, making accurate diagnosis challenging. Testing remains crucial to confirm a COVID-19 diagnosis and guide appropriate treatment and isolation measures.
Vaccine Effectiveness Against Cicada
Initial studies suggest that current vaccines may be less effective against the Cicada variant, but they still provide protection against severe illness, according to the World Health Organization. This finding is consistent with observations from previous variant emergence, where vaccines have demonstrated reduced efficacy against infection but continued protection against serious outcomes. Experts anticipate the potential for future vaccine updates to address the new variant, leveraging the existing technology that allows for rapid modification of vaccine formulations.
Protecting Yourself from the Cicada Variant
Health officials recommend adhering to standard preventative measures, such as getting tested when symptoms appear, staying home when sick, wearing masks in crowded indoor spaces, and consulting with a healthcare provider about booster doses. Vaccination, particularly for older adults and individuals with underlying health conditions, remains a cornerstone of protection against severe complications from the virus. Staying up-to-date with recommended vaccinations is the most effective way to reduce the risk of hospitalization and death.
Disclaimer: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The CDC is expected to provide an updated assessment of the Cicada variant’s prevalence and impact during its next advisory committee meeting on March 15, 2026. Continued monitoring and research will be vital to understanding the long-term implications of this new variant. Share this information with your network and stay informed about the latest developments.
